Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of GTX-102 in Angelman syndrome
MOH_2024-09-10_013630Phase 3Not yet recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Sep 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apazunersen in Angelman syndrome (AS), sponsored by Ultragenyx Pharmaceutical Inc. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
apazunersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on MOH_2024-09-10_013630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-10_013630.